News
Scientists find muscle relaxant reduces Huntington's disease severity
Nov 25 2011
Scientists have used a muscle relaxant to successfully reduce the severity of Huntington's disease in laboratory mice.
Using a RyanR inhibitor, researchers from the University of Texas Southwestern Medical Center recorded less of a decline in coordination, which they measured using beam walking and footprint patterns in mice with a disease with similar characteristics to the degenerative condition.
Huntington's is caused by the recessive mutation of a gene protein, which releases abnormal quantities of calcium within neurons, which in turn disrupts connections eventually leading to their death.
Lead researcher Dr Ilya Bezprozvanny explained: "Our results suggest that RyanR inhibitors, such as Dantrolene, should be considered as future treatments to slow down the effects of diseases like Huntington's."
Recent research published in the Lancet Neurology journal indicated the drug pridopidine stabilises dopamine signaling in the brain, leading scientists to recommend further investigation as a possible treatment for Huntington's.
Posted by Neil Clark
Digital Edition
Lab Asia Dec 2025
December 2025
Chromatography Articles- Cutting-edge sample preparation tools help laboratories to stay ahead of the curveMass Spectrometry & Spectroscopy Articles- Unlocking the complexity of metabolomics: Pushi...
View all digital editions
Events
Jan 21 2026 Tokyo, Japan
Jan 28 2026 Tokyo, Japan
Jan 29 2026 New Delhi, India
Feb 07 2026 Boston, MA, USA
Asia Pharma Expo/Asia Lab Expo
Feb 12 2026 Dhaka, Bangladesh



